# Procter & Gamble Health Limited (PGHL)

> PGHL closed at ₹5,699.50 on 30 Oct 2026, trailing P/E 26.5, market cap ₹9,461 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Procter & Gamble Health Limited (NSE: PGHL) closed at ₹5,699.50 on 30 Oct 2026, -8.7% over one year, against a 52-week range of ₹4,707.00 – ₹6,975.00.

In the quarter ended 30 Jun 2026 (standalone, filed 6 Aug 2026) it reported revenue of ₹364 cr and net profit of ₹96 cr, a 26.4% net margin; revenue grew 7.4% and profit grew 45.4% year on year.

On four consecutive filed quarters its trailing P/E is 26.5; since 17 Jun 2025 its own P/E has ranged from 23.3 to 46.6 (median 37.5), and today's reading is higher than 11% of those 338 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 73.3%, ROCE 88.2%, debt-to-equity 0.00, Piotroski F-score 7 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 89% of 63 sector peers; PBT margin higher than 92% of 63 sector peers; ROE higher than 100% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹5,699.50 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | +5.2% / +10.9% / -8.7% |
| 52-week low – high | ₹4,707.00 – ₹6,975.00 |
| Market capitalisation | ₹9,461 cr |
| Trailing P/E | 26.5 |
| Price / book | 18.04 |
| EV / EBITDA | 18.0 |
| Earnings yield | 3.8% |
| TTM EPS | ₹214.99 |
| TTM net profit | ₹357 cr |
| Quarter revenue | ₹364 cr |
| Quarter net profit | ₹96 cr |
| Net margin | 26.4% |
| Revenue growth (YoY) | +7.4% |
| Profit growth (YoY) | +45.4% |
| Return on equity | 73.3% |
| ROCE | 88.2% |
| Debt / equity | 0.00 |
| Current ratio | 2.18 |
| Free cash flow | ₹322 cr |
| Piotroski F-score | 7 / 9 |
| Average daily turnover (50 days) | ₹4.7 cr |

## Questions

### What is the P/E ratio of Procter & Gamble Health Limited?

Procter & Gamble Health Limited's trailing P/E is 26.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 17 Jun 2025 its P/E has ranged 23.3–46.6.

### What were Procter & Gamble Health Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Procter & Gamble Health Limited reported revenue of ₹364 cr and net profit of ₹96 cr (standalone), filed with the exchange on 6 Aug 2026.

### What is Procter & Gamble Health Limited's ROE?

Return on equity is 73.3% based on the balance sheet dated 31 Mar 2026.

### Does Procter & Gamble Health Limited have debt?

Debt-to-equity is 0.00 on the balance sheet dated 31 Mar 2026.

### What is PGHL's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, PGHL traded between ₹4,707.00 and ₹6,975.00.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/PGHL

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._